Arizona State Retirement System Acquires 2,363 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Arizona State Retirement System grew its holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTLFree Report) by 20.2% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 14,046 shares of the company’s stock after purchasing an additional 2,363 shares during the period. Arizona State Retirement System’s holdings in Zentalis Pharmaceuticals were worth $282,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in ZNTL. JPMorgan Chase & Co. increased its holdings in Zentalis Pharmaceuticals by 284.2% during the first quarter. JPMorgan Chase & Co. now owns 105,579 shares of the company’s stock worth $4,871,000 after buying an additional 78,102 shares during the last quarter. US Bancorp DE increased its holdings in Zentalis Pharmaceuticals by 378.9% during the first quarter. US Bancorp DE now owns 1,451 shares of the company’s stock worth $67,000 after buying an additional 1,148 shares during the last quarter. MetLife Investment Management LLC increased its holdings in Zentalis Pharmaceuticals by 57.0% during the first quarter. MetLife Investment Management LLC now owns 19,665 shares of the company’s stock worth $907,000 after buying an additional 7,139 shares during the last quarter. Rhumbline Advisers increased its holdings in Zentalis Pharmaceuticals by 7.0% during the first quarter. Rhumbline Advisers now owns 37,923 shares of the company’s stock worth $1,750,000 after buying an additional 2,475 shares during the last quarter. Finally, Dimensional Fund Advisors LP acquired a new position in Zentalis Pharmaceuticals during the first quarter worth $4,221,000.

Insider Activity

In other Zentalis Pharmaceuticals news, CEO Kimberly Blackwell bought 5,000 shares of Zentalis Pharmaceuticals stock in a transaction dated Monday, November 13th. The stock was bought at an average price of $10.29 per share, with a total value of $51,450.00. Following the completion of the transaction, the chief executive officer now owns 254,800 shares in the company, valued at approximately $2,621,892. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 6.10% of the stock is currently owned by company insiders.

Zentalis Pharmaceuticals Stock Performance

Shares of Zentalis Pharmaceuticals stock opened at $11.50 on Friday. The firm has a 50-day moving average of $13.65 and a 200-day moving average of $17.84. The stock has a market cap of $813.81 million, a PE ratio of -2.48 and a beta of 1.65. Zentalis Pharmaceuticals, Inc. has a 52-week low of $9.56 and a 52-week high of $31.46.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on ZNTL shares. SVB Leerink downgraded shares of Zentalis Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $15.00 target price on the stock. in a report on Tuesday, November 7th. Wedbush cut shares of Zentalis Pharmaceuticals from an “outperform” rating to a “neutral” rating and reduced their price objective for the stock from $38.00 to $12.00 in a research report on Wednesday, November 8th. Morgan Stanley reduced their price objective on shares of Zentalis Pharmaceuticals from $55.00 to $38.00 and set an “overweight” rating for the company in a research report on Tuesday, November 7th. HC Wainwright reduced their price objective on shares of Zentalis Pharmaceuticals from $55.00 to $46.00 and set a “buy” rating for the company in a research report on Tuesday, November 7th. Finally, Leerink Partnrs cut shares of Zentalis Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Tuesday, November 7th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, Zentalis Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $38.14.

View Our Latest Stock Report on ZNTL

Zentalis Pharmaceuticals Profile

(Free Report)

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.

Read More

Want to see what other hedge funds are holding ZNTL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTLFree Report).

Institutional Ownership by Quarter for Zentalis Pharmaceuticals (NASDAQ:ZNTL)

Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.